These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 16335701)
1. [Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer]. Prausová J; Kubácková K; Linke Z; Kubala E; Pipková R; Hladíková J Cas Lek Cesk; 2005; 144(11):747-51; discussion 752. PubMed ID: 16335701 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736 [TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin. Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456 [TBL] [Abstract][Full Text] [Related]
6. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A; Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184 [TBL] [Abstract][Full Text] [Related]
8. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234 [TBL] [Abstract][Full Text] [Related]
9. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley AC; Sargent DJ; Alberts SR; Grothey A; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM Cancer; 2007 Aug; 110(3):670-7. PubMed ID: 17559146 [TBL] [Abstract][Full Text] [Related]
10. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618 [TBL] [Abstract][Full Text] [Related]
11. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F; J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722 [TBL] [Abstract][Full Text] [Related]
12. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Lorizzo K; Fazio N; Radice D; Boselli S; Ariu L; Zampino MG; Nolè F; Magni E; Ardito R; Minchella I; Rocca A; Di Meglio G; Squadroni M; de Braud F Cancer Chemother Pharmacol; 2009 Jul; 64(2):301-6. PubMed ID: 19034450 [TBL] [Abstract][Full Text] [Related]
13. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage. Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156 [TBL] [Abstract][Full Text] [Related]
14. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Maiello E; Gebbia V; Giuliani F; Paoletti G; Gebbia N; Borsellino N; Cartenì G; Pezzella G; Manzione L; Romito S; Lopez M; Colucci G; Ann Oncol; 2005 May; 16 Suppl 4():iv56-60. PubMed ID: 15923431 [TBL] [Abstract][Full Text] [Related]
15. [Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection]. Bajetta E; Cappuzzo F Ann Ital Chir; 1996; 67(6):827-30. PubMed ID: 9214274 [TBL] [Abstract][Full Text] [Related]
16. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer. Schrag D; Weiser M; Schattner M; Shia J; Akhurst T J Clin Oncol; 2005 Mar; 23(9):1799-802. PubMed ID: 15774773 [No Abstract] [Full Text] [Related]
17. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Goldberg RM; Erlichman C Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093 [TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Folprecht G; Köhne CH; Lutz MP Cancer Treat Res; 2007; 134():425-40. PubMed ID: 17633071 [No Abstract] [Full Text] [Related]